Receptor-selective IL-4 mutein modulates inflammatory vascular cell phenotypes and attenuates atherogenesis in apolipoprotein E-knockout mice

Experimental and Molecular Pathology

Volumn 99, Issue 1, 2015, Pages 116-127

  Lin, Yanhui ^a,b   Chen, Zhiheng ^a   Kato, Seiya ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Apo E knockout mouse; Atherogenesis; Endothelial cells; IL 4; Macrophages; Vascular smooth muscle cells

Indexed keywords

ADENOVIRUS VECTOR; APOLIPOPROTEIN E; BETA GALACTOSIDASE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 4; INTERLEUKIN 4 MUTEIN; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 4 RECEPTOR GAMMA; INTERLEUKIN RECEPTOR; MUTANT PROTEIN; STAT6 PROTEIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; STAT6 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; BLOOD VESSEL; C57BL 6 MOUSE; CELL ISOLATION; CELL LINEAGE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; GENETIC TRANSFECTION; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATORY CELL; KNOCKOUT MOUSE; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; PLASMID; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPLEEN CELL; TH2 CELL; UPREGULATION; VASCULAR CELL; VASCULAR DISEASE; ADENOVIRIDAE; ANIMAL; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; C57BL MOUSE; CELL LINE; CYTOLOGY; GENE VECTOR; GENETICS; MALE; METABOLISM; SPLEEN;

ADENOVIRIDAE; MURINAE; MUS;

ADENOVIRIDAE; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL LINE; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-13; INTERLEUKIN-4; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; RECEPTORS, INTERLEUKIN-4; SIGNAL TRANSDUCTION; SPLEEN; STAT6 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84934999521     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2015.06.007     Document Type: Article

References (55)

1. Andersson A., Grunewald S.M., Duschl A., Fischer A., DiSanto J.P. Mouse macrophage development in the absence of the common gamma chain: defining receptor complexes responsible for IL-4 and IL-13 signaling. Eur. J. Immunol. 1997, 27:1762-1768.
2. Andersson J., Libby P., Hansson G.K. Adaptive immunity and atherosclerosis. Clin. Immunol. 2010, 13:33-46.
3. Antoniu S.A. Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema. Curr. Opin. Investig. Drugs 2010, 11:1286-1294.
4. Bönsch D., Kammer W., Lischke A., Friedrich K. Species-specific agonist/antagonist activities of human interleukin-4 variants suggest distinct ligand binding properties of human and murine common receptor gamma chain. J. Biol. Chem. 1995, 270:8452-8457.
5. Boothby M., Mora A.L., Aronica M.A., Youn J., Sheller J.R., Goenka S., Stephenson L. IL-4 signaling, gene transcription regulation, and the control of effector T cells. Immunol. Res. 2001, 23:179-191.
6. Cortes J.R., Perez-G M., Rivas M.D., Zamorano J. Kaempferol inhibits IL-4-induced STAT6 activation by specifically targeting JAK3. J. Immunol. 2007, 179:3881-3887.
7. Davenport P., Tipping P.G. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Pathol. 2003, 163:1117-1125.
8. Doucet C., Giron-Michel J., Canonica G.W., Azzarone B. Human lung myofibroblasts as effectors of the inflammatory process: the common receptor gamma chain is induced by Th2 cytokines, and CD40 ligand is induced by lipopolysaccharide, thrombin and TNF-alpha. Eur. J. Immunol. 2002, 32:2437-2449.
9. Grunewald S.M., Kunzmann S., Schnarr B., Ezernieks J., Sebald W., Duschl A. A murine interleukin-4 antagonistic mutant protein completely inhibits interleukin-4-induced cell proliferation, differentiation, and signal transduction. J. Biol. Chem. 1997, 272:1480-1483.
10. Guillot C., Coathalem H., Chetritt J., David A., Lowenstein P., Gilbert E., Tesson L., Van Rooijen N., Cuturi M.C., Soulillou J.P., Anegon I. Lethal hepatitis after gene transfer of IL-4 in the liver is independent of immune responses and dependent on apoptosis of hepatocytes: a rodent model of IL-4-induced hepatitis. J. Immunol. 2001, 166:5225-5235.
11. Hamilton T.A., Ohmori Y., Tebo J. Regulation of chemokine expression by antiinflammatory cytokines. Immunol. Res. 2002, 25:229-245.
12. Heller N.M., Qi X., Junttila I.S., Shirey K.A., Vogel S.N., Paul W.E., Keegan A.D. Type I IL-4Rs selectively activate IRS-2 to induce target gene expression in macrophages. Sci. Signal. 2008, 1:ra17.
13. Junttila I.S., Mizukami K., Dickensheets H., Meier-Schellersheim M., Yamane H., Donnelly R.P., Paul W.E. Tuning sensitivity to IL-4 and IL-13: differential expression of IL-4Rα, IL-13Rα1, and γc regulates relative cytokine sensitivity. J. Exp. Med. 2008, 205:2595-2608.
14. Kato S., Yamaguchi M., Fujii T., Miyagi N., Terasaki M., Hamada T., Sugita Y. Overexpression of p21Waf-1 in vascular smooth muscle cells: regulation of proliferation, differentiation, and cell size. Exp. Mol. Pathol. 1999, 66:39-52.
15. Kelly-Welch A.E., Hanson E.M., Boothby M.R., Keegan A.D. Interleukin-4 and interleukin-13 signaling connections maps. Science 2003, 300:1527-1528.
16. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern. Med. Rev. 2003, 8:223-246.
17. King V.L., Szilvassy S.J., Daugherty A. Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/- mice. Arterioscler. Thromb. Vasc. Biol. 2002, 22:456-461.
18. King V.L., Cassis L.A., Daugherty A. Interleukin-4 does not influence development of hypercholesterolemia or angiotensin II-induced atherosclerotic lesions in mice. Am. J. Pathol. 2007, 171:2040-2047.
19. Kobayashi M., Inoue K., Warabi E., Minami T., Kodama T. A simple method of isolating mouse aortic endothelial cells. J. Atheroscler. Thromb. 2005, 12:138-142.
20. Koga M., Kai H., Yasukawa H., Yamamoto T., Kawai Y., Kato S., Kusaba K., Kai M., Egashira K., Kataoka Y., Imaizumi T. Inhibition of progression and stabilization of plaques by postnatal interferon-gamma function blocking in ApoE-knockout mice. Circ. Res. 2007, 101:348-356.
21. Kozarsky K.F., Jooss K., Donahee M., Strauss J.F., Wilson J.M. Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat. Genet. 1996, 13:54-62.
22. Kruse N., Tony H.P., Sebald W. Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement. EMBO J. 1992, 11:3237-3244.
23. LaPorte S.L., Juo Z.S., Vaclavikova J., Colf L.A., Qi X., Heller N.M., Keegan A.D., Garcia K.C. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 2008, 132:259-272.
24. Lee Y.W., Hirani A.A. Role of interleukin-4 in atherosclerosis. Arch. Pharm. Res. 2006, 29:1-15.
25. Lunov O., Simmet T., Rouis M., Hadri E.l, Mahmood D.F., Couchie D., Jguirim-Souissi I., Genze F., Diderot V., Syrovets T., Lunov O., Simmet T., Rouis M. Thioredoxin-1 promotes anti-inflammatory macrophages of the M2 phenotype and antagonizes atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1445-1452.
26. Masinovsky B., Urdal D., Gallatin W.M. IL-4 acts synergistically with IL-1 beta to promote lymphocyte adhesion to microvascular endothelium by induction of vascular cell adhesion molecule-1. J. Immunol. 1990, 145:2886-2895.
27. Mijatovic T., Kruys V., Caput D., Defrance P., Huez G. Interleukin-4 and -13 inhibit tumor necrosis factor-alpha mRNA translational activation in lipopolysaccharide-induced mouse macrophages. J. Biol. Chem. 1997, 272:14394-14398.
28. Morioka T., Yamanaka K., Mori H., Omoto Y., Tokime K., Kakeda M., Kurokawa I., Gabazza E.C., Tsubura A., Yasutomi Y., Mizutani H. IL-4/IL-13 antagonist DNA vaccination successfully suppresses Th2 type chronic dermatitis. Br. J. Dermatol. 2009, 160:1172-1179.
29. Morishima Y., Ishii Y. Targeting Th2 cytokines in fibrotic diseases. Curr. Opin. Investig. Drugs 2010, 11:1229-1238.
30. Mueller T.D., Zhang J.L., Sebald W., Duschl A. Structure, binding, and antagonists in the IL-4/IL-13 receptor system. Biochim. Biophys. Acta 2002, 1592:237-250.
31. Murahashi N., Sasaguri Y., Ohuchida M., Kakita N., Morimatsu M. Immortalization of human aortic smooth muscle cells with origin-minus simian virus 40 DNA. Biotechnol. Appl. Biochem. 1992, 16:152-160.
32. Murata T., Taguchi J., Puri R.K., Mohri H. Sharing of receptor subunits and signal transduction pathway between the IL-4 and IL-13 receptor system. Int. J. Hematol. 1999, 69:13-20.
33. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011, 11:723-737.
34. Nakashima Y., Plump A.S., Raines E.W., Breslow J.L., Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. 1994, 14:133-140.
35. Nishikubo K., Murata Y., Tamaki S., Sugama K., Imanaka-Yoshida K., Yuda N., Kai M., Takamura S., Sebald W., Adachi Y., Yasutomi Y. A single administration of interleukin-4 antagonistic mutant DNA inhibits allergic airway inflammation in a mouse model of asthma. Gene Ther. 2003, 10:2119-2125.
36. Noble A., Kemeny D.M. Interleukin-4 enhances interferon-gamma synthesis but inhibits development of interferon-gamma-producing cells. Immunology 1995, 85:357-363.
37. Orlandi A., Bennett M. Progenitor cell-derived smooth muscle cells in vascular disease. Biochem. Pharmacol. 2010, 79:1706-1713.
38. Paul W.E. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 1991, 7:1859-1870.
39. Ramalingam T.R., Pesce J.T., Sheikh F., Cheever A.W., Mentink-Kane M.M., Wilson M.S., Stevens S., Valenzuela D.M., Murphy A.J., Yancopoulos G.D., Urban J.F., Donnelly R.P., Wynn T.A. Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain. Nat. Immunol. 2008, 9:25-33.
40. Reinemer P., Sebald W., Duschl A. The interleukin-4-receptor: from recognition mechanism to pharmacological target structure. Angew. Chem. Int. Ed. Engl. 2000, 39:2834-2846.
41. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340:115-126.
42. Rutschman R., Lang R., Hesse M., Ihle J.N., Wynn T.A., Murray P.J. Cutting edge: Stat6-dependent substrate depletion regulates nitric oxide production. J. Immunol. 2001, 166:2173-2177.
43. Sasaguri T., Arima N., Tanimoto A., Shimajiri S., Hamada T., Sasaguri Y. A role for interleukin 4 in production of matrix metalloproteinase 1 by human aortic smooth muscle cells. Atherosclerosis 1998, 138:247-253.
44. Schnyder B., Lugli S.M., Schnyder-Candrian S., Eng V.M., Moser R., Banchereau J., Ryffel B., Car B.D. Biochemical and morphological characterization of vascular and lymphocytic interleukin-4 receptors. Am. J. Pathol. 1996, 149:1369-1379.
45. Shanafelt A.B., Forte C.P., Kasper J.J., Sanchez-Pescador L., Wetzel M., Gundel R., Greve J.M. An immune cell-selective interleukin 4 agonist. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:9454-9458.
46. Simões S., Slepushkin V., Gaspar R., Pedroso de Lima M.C., Düzgünes N. Successful transfection of lymphocytes by ternary lipoplexes. Biosci. Rep. 1999, 19:601-609.
47. Steinmetz M., Nickenig G., Werner N. Endothelial-regenerating cells: an expanding universe. Hypertension 2010, 55:593-599.
48. Sundström C., Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int. J. Cancer 1976, 17:565-577.
49. Tomkinson A., Duez C., Cieslewicz G., Pratt J.C., Joetham A., Shanafelt M.C., Gundel R., Gelfand E.W. A murine IL-4 receptor antagonist that inhibits IL-4- and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. J. Immunol. 2001, 166:5792-5800.
50. Tsuchiya S., Yamabe M., Yamaguchi Y., Kobayashi Y., Konno T., Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int. J. Cancer 1980, 26:171-176.
51. Williams R.L., Courtneidge S.A., Wagner E.F. Embryonic lethalities and endothelial tumors in chimeric mice expressing polyoma virus middle T oncogene. Cell 1988, 52:121-131.
52. Wright P.S., Cooper J.R., Kropp K.E., Busch S.J. Induction of vascular cell adhesion molecule-1 expression by IL-4 in human aortic smooth muscle cells is not associated with increased nuclear NF-κB levels. J. Cell. Physiol. 1999, 180:381-389.
53. Zavorotinskaya T., Tomkinson A., Murphy J.E. Treatment of experimental asthma by long-term gene therapy directed against IL-4 and IL-13. Mol. Ther. 2003, 7:155-162.
54. Zhou X., Stemme S., Hansson G.K. Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am. J. Pathol. 1996, 149:359-366.
55. Zhou X., Paulsson G., Stemme S., Hansson G.K. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J. Clin. Invest. 1998, 101:1717-1725.